Cover Image

創傷護理(傳統、先進、再生) - 全球市場、競爭企業、機會:分析與預測

Wound Care - Traditional, Advanced and Regenerative - Global Markets, Competitors and Opportunities: 2015-2020 Analysis and Forecasts

出版商 Amadee & Company, Inc. 商品編碼 322978
出版日期 內容資訊 英文 202 Pages
Back to Top
創傷護理(傳統、先進、再生) - 全球市場、競爭企業、機會:分析與預測 Wound Care - Traditional, Advanced and Regenerative - Global Markets, Competitors and Opportunities: 2015-2020 Analysis and Forecasts
出版日期: 2015年01月16日 內容資訊: 英文 202 Pages




  • 報告的目的
  • 調查手法和資訊來源
  • 統計相關註解


  • 創傷
  • 分類
  • 發生
  • 傷口護理複雜的流程
  • 凝固/發炎
  • 增生期
  • 重塑與疤痕形成
  • 慢性傷口需要先進創傷護理
  • TIME策略
  • 複數類型的傷口敷料
  • 泡沫敷料
  • 抗菌性敷料
  • 水凝膠
  • 親水膠體
  • 生物介面和皮膚替代品
  • 修復 vs. 再生
  • 法規當局的創傷護理產品的核准途徑
  • 510(k)必要條件
  • I級產品
  • II級產品
  • III級產品
  • 創傷護理產品的償付
  • 生物學性物質
  • 細胞/組織利用產品的新償付規則
  • 美國的創傷護理償付的轉移
  • 轉移後
  • 創傷護理產品的流通
  • DFU市場機會
  • VLF市場機會
  • DFU和VLU的發病率
  • 莫大的負擔
  • 標準治療
  • 顛覆性技術:PRFE
  • PRFE的傷口護理
  • 微小循環與血管新生


  • 級/市場區隔
  • 全球創傷護理市場
  • 全球創傷護理市場:各地區
  • 全球創傷護理市場:各產品級
  • 傳統傷口護理市場:各產品區隔
  • 傷口縫合產品市場:各產品區隔
  • 創傷管理市場:各產品區隔
  • 先進創傷護理市場:各產品區隔
  • 企業的市場佔有率




A major study and financial analysis of Traditional, Advanced and Regenerative Wound Care markets during the 2015 to 2020 period.

Comprehensive information and evaluation of the global Wound Care products market, with detailed analysis of manufacturers, segmentation, product offerings, competitive shares, financial performance, technology developments and market drivers. Additionally, 20 key Wound Care product suppliers are fully analyzed and profiled.

A must-read compendium of information and analysis that will provide executives with a significant knowledge of global market, product, technology and financial developments in this industry. Hard factual information in 202 pages, illustrated with 53 tables and 42 charts and figures.

The only published report of its kind, with in-depth detail not found elsewhere in similar studies.

Table of Contents




  • Report Objectives
  • Methodology and Sources
  • Statistical Notes


  • Wounds
  • Classifications
  • Occurrence
  • Wound Healing Is a Complex Process
  • Coagulation/inflammation
  • Proliferative Phase
  • Remodeling and Scar Formation
  • Chronic Wounds Require Advanced Wound Care
  • TIME Strategy
  • Multiple Types of Wound Dressings Exist
  • Foam Dressings
  • Antimicrobial Dressings
  • Hydrogels
  • Hydrocolloids
  • Bioengineered Skin and Skin Substitutes
  • Repair vs. Regeneration
  • Regulatory Approval Pathway for Wound Care Products
  • 510(k) Requirements
  • Class I Products
  • Class II Products
  • Class III Products
  • Reimbursement of Wound Care Products
  • Biologic Substances
  • New Reimbursement Rule for Cellular/Tissue-Based Products
  • Shifting U.S. Wound Care Reimbursement
  • Post Shift
  • Distribution of Wound Care Products
  • DFU Market Opportunities
  • VLF Market Opportunities
  • Incidence of DFUs and VLUs
  • Tremendous Burden
  • Standard of Care
  • Disruptive Technology: Pulsed Radio Frequency Energy
  • PRFE Wound Healing
  • Microcirculation and Angiogenesis
  • PRFE/PEMF Market


  • Classes/Segments
  • Global Wound Care Market
  • Global Wound Care Market by Region
  • Global Wound Care Market by Product Class
  • Traditional Wound Care Market by Product Segment
  • Wound Closure Market by Product Segment
  • Wound Management Market by Product Segment
  • Advanced Wound Care Market by Product Segment
  • Company Market Shares


3M Company

  • (Company Overview, 3M Health Care Ltd., Wound Care Sales)

Advanced Medical Solutions Group plc

  • (Company Overview, Wound Care, Products, R&D, Facilities, Geography, LiquiBand, Global Tissue Adhesives Market, Market Share, Distributors, Covidien Agreement, New Octyl Formulation, Sales Upside, Hernia Mesh Fixation, Future Indications - Pelvic Organ Prolapse, Potential Sales, ActivHeal, Financials)

Alliqua BioMedical, Inc.

  • (Company Overview, Contract Manufacturing, Integrated Portfolio of Wound Care Products, Transactions Executed to Build the Current Portfolio, Currently Markets Six Products, Hydress, SilverSea, TheraBond 3D®, Sorbion HRT Product Line: satchet S® and sorbion sana®, Competition, Regenerative Wound Care Products (Partnered with Celgene), Human Placental Tissue, Celgene Cellular Therapeutics (CCT), Biovance® (Decellurized Human Amniotic Membrane), Competition, Biovance® Regulation, Celgene ECM-Based Products, Complete Portfolio In Advanced Wound Care, Celgene Backing Validates, MiMedx vs. Aliiqua Product Revenues, Reimbursement Pathway Paved By Peers, Clinical Evidence Is Building, DDHAM Use Registry Study, Under New Leadership, Sales Force Growing, Ambitious Long-Term Targets, Financials)

Avita Medical Ltd.

  • (Company Overview, Regenerative Medicine, Protocol Adjustments To U.S. Burn Trial, Shifting Focus In The UK, Chronic Wounds, Future Uncertain, Financials)

Centaur Guernsey L.P. Inc.

  • (Company Overview, Advanced Wound Therapeutics, Advanced Devices, NPSM, Advanced Wound Dressings, Customers, Sales and Marketing, Competition, Regenerative Medicine, Customers, Competition, Systagenix Acquisition, CelluTome Acquisition, GRAFTJACKET Agreement, Health Care Initiatives and Reimbursement, New Reimbursement Rates, Consolidation Increasing, Foreign Regulations, Financials)

Coloplast A/S

  • (Company Overview, Distribution, Geography, Wound and Skin Care Business, Wound Care, NPWT, Silicon-Based Products, Wound Care Addressable Market, Two Step Margin Expansion, Americas NPWT Outlook, Product Growth Drivers, Consolidation Unavoidable, Market Shares, Financials)

Covidien plc

  • (Company Overview, Products, Wound Care, Sales)

Cytomedix, Inc.

  • (Company Overview, Products, Pipeline, Business Reorganization, AutoloGel, Beneficiary of CMS's New Bundling Rules, Long-Term Acute Care Hospitals, Key Competitors, Financials)

CytoTools AG

  • (Company Overview, Corporate Structure, Key Projects in Development, Strategy, Financials)

Derma Sciences, Inc.

  • (Company Overview, Products, Advanced Wound Care, Pharmaceutical Wound Care, Traditional Wound Care, Manufacturing, Distribution, Customers, R&D, Geography, Tissue Technology in Early Stages, Distribution Expansion Pays Off in 2015, DSC127 - Phase III Trials Ongoing, Partnership Opportunities, Financials)

Essex Bio-Technology Ltd.

  • (Company Overview, Long-Term Patent Protection, Partnership with Pfizer, Market Share, 20% Growth for Ophthalmic Drugs, Surface Wound Healing Growth Driver, More Reliance on Direct Sales, New Manufacturing Capacity, R&D Pipeline, Financials)

Japan Tissue Engineering Co., Ltd.

  • (Company Overview, Financials)

Johnson & Johnson

  • (Company Overview, Wound Care, Sutures, Financials)

Macrocure Ltd

  • (Company Overview, CureXcell, Hypo-Osmotic Shock, How CureXcell Heals Wounds, Production Process, Behind the Wound Healing Process, Composition of Wound Healing, Used in Hard-to-Heal Chronic Wounds, CureXcell vs. Alternative Advanced Therapies, Negative Pressure Wound Therapy, Apligraf and Dermagraft Are the Likely Baseline by which CureXcell Will Be Judged, Lower Treatment Costs Than Alternatives, Clinical Summary, Efficacious in Hard-to-Heal Wounds, Clinical Frame of Reference, CureXcell Promising But Data Limited, Fewer Treatments Than Most Competing AWC Products, Addressable DFU and VLU Markets, CureXcell DFU and VLU Market Opportunities, Profitability, Catalysts and Milestones, Competition, Note on HCT/P)

MiMedx Group, Inc.

  • (Company Overview, Transforming from Wounds into Regenerative Medicine, Prostatectomy Market Opportunity, Amniotic Tissue Is Not the Same Across Competitors, Direct Distribution Gaining Critical Mass, Gaining Coverage/Reimbursement, CMS Changes in Reimbursement Create Disruptive Opportunity, Path Forward for Micronized Products, Financials)

Novadaq Technologies Inc.

  • (Company Overview, Technology and Products, LUNA, Diabetic Applications, Game Changer, First Wound Care Diagnostic System, Luna Drivers, LUNA Economics, LUNA Profits, SerenaGroup Partnership, LifeNet Health Agreement, Globalization Strategy, Financials)

Osiris Therapeutics, Inc.

  • (Company Overview, Products, Grafix, BLA Filing, Medicare Reimbursement, Grafix Pipeline, Financials)

SANUWAVE Health, Inc.

  • (Company Overview, dermaPACE®, Shock Wave Technology, Strong Patents, Installed Base, Distribution, Phase III Trial, Financials)

Smith & Nephew Plc

  • (Company Overview, Advanced Wound Management, Market Share Battle, Bioactives, Significant ASP Increases and Limited Competition, HP802-247, Reimbursement Uncertain, Bundling a Concern, Pico Could Take Share, Competition Increasing, Pico Advantages, Loss of Renasys, Financials)

Tissue Regenix Group plc

  • (Company Overview, Wound Care, Q-Code Confirmed, Possible Takeover Candidate)


  • 1. Chronic Wounds and Their Economic Impact in the U.S.
  • 2. Chronic Wound Management Antiseptics and Formulations
  • 3. Sample of Skin Substitutes by Cost Bucket Under CMS 2014 Bundle
  • 4. Reported Wound Healing Outcomes With Pulsed Radio Frequency Energy
  • 5. Global Wound Care Market (USD Billion): 2015-2020
  • 6. Global Wound Care Market by Region (USD Billion): 2015-2020
  • 7. Global Wound Care Market by Product Class (USD Million): 2015-2020
  • 8. Traditional Wound Care Market by Product Segment (USD Million): 2015-2020
  • 9. Wound Closure Market by Product Segment (USD Million): 2015-2020
  • 10. Wound Management Market by Product Segment (USD Million): 2015-2020
  • 11. Wound Management Market by Product Type (USD Million): 2015-2020
  • 12. Global Wound Care Market Shares by Company (USD Million): 2014
  • 13. Global Traditional Wound Care Market Shares by Company (USD Million): 2014
  • 14. Global Advanced Wound Care Market Shares by Company (USD Million): 2014
  • 15. Global Regenerative Wound Care Market Shares by Company (USD Million): 2014
  • 16. The LiquiBand Portfolio
  • 17. LiquiBand U.S. Sales (GBP Million) and Market Share (%): 2013-2018
  • 18. LiquiBand U.S. Sales (USD Million), Market Share (%) and Sales Booked by AMS: 2013-2018
  • 19. LiquiBand Potential Peak Annual Sales (GBP Million) from HMF and POP Repair (Number) by 2018
  • 20. LiquiBand Likely Sales (GBP Million) from HMF and POP in Europe and U.S.: 2014-2018
  • 21. Biovance® Indications
  • 22. Alliqua's Main Competitors In Skin Substitute Market
  • 23. Eight Medicare Administrative Contactors: Jurisdiction, States, Number of Beneficiaries, Claims Volume
  • 24. Study Results Biovance® vs. Nanocrystalline
  • Silver
  • 25. Alliqua BioMedical Revenue Forecast (USD Million): 2012-2020
  • 26. Avita Medical Ltd. Income Statement (USD Thousand): 2013-2016
  • 27. Centaur Guernsey Income Statement: 2009-2013
  • 28. Coloplast Addressable Markets, Markets Growth, Market Shares, Key Competitors, Drivers by Division (DKK Billion): 2014
  • 29. Coloplast Wound Care Disease Areas, Customer Groups, Key Products, Distribution of Revenue by Product: 2014
  • 30. Coloplast Wound Care Addressable Markets by Region (DKK, USD Billion): 2013-2023
  • 31. Coloplast European Wound Care Addressable Market by Product (DKK Billion) and Penetration Rate (%): 2013-2023
  • 32. Coloplast Rest of World Wound Care Addressable Market by Product (DKK Billion) and Penetration Rate (%): 2013-2023
  • 33. Coloplast Americas Wound Care Addressable Market by Product (DKK Billion) and Penetration Rate (%): 2013-2023
  • 34. Coloplast NPWT Americas Revenue by Product (DKK Billion) and Growth Rate (%): 2013-2023
  • 35. Coloplast Income Statement by Segment (DKK Million): 2005-2017
  • 36. CytoTools Income Statement: 2011-2020
  • 37. Derma Sciences Income Statement (USD thousands): 2012-2016
  • 38. Essex Bio-Technology Income Statement (HKD Million): 2011-2013
  • 39. Advanced Wound Care Treatment Cost Comparison
  • 40. Summary of Most Relevant CureXcell Study Data
  • 41. Comparison of Advanced Wound Trial Patient Characteristics and Results
  • 42. Addressable Market for Hard-to-Heal Diabetic Foot Ulcers and Venous Leg Ulcers by Region (Million) and Incidence (%): 2014-2030
  • 43. Macrocure Revenue for Hard-to-Heal Diabetic Foot Ulcers and Venous Leg Ulcers by Region (USD Million) and Penetration (%): 2020-2030
  • 44. Macrocure Revenue (USD Million): 2014-2030
  • 45. MiMedx Revenue by Product (USD Thousand): 2010-2016
  • 46. LUNA: Wound Care U.S. Recurring Revenue Model
  • 47. Novadaq Potential Applications by Patients Per Year: U.S. Number of Procedures
  • 48. Novadaq Technologies Income Statement (USD Million): 2012-2016
  • 49. Osiris' Grafix Product Pipeline
  • 50. Osiris Therapeutics Income Statement: 2013-2020
  • 51. Smith & Nephew Wound Bioactives Revenue (USD Million) and TRx Growth (%): 2013-2018
  • 52. Comparison of Selected Portable NPWT Products by Manufacturer
  • 53. Smith & Nephew Income Statement (USD Million): 2011-2018


  • 1. Coagulation/Inflammation Phase of Wound Healing
  • 2. Proliferative Phase of Wound Healing
  • 3. Remodeling and Scar Formation Phase of Wound Healing
  • 4. Chronic Wound Management
  • 5. Diabetic Foot Ulcer Examples
  • 6. Venous Leg Ulcer Examples
  • 7. Annual DFU and VLU Incidence by Type in U.S., EU5, Japan (Thousands): 2013
  • 8. U.S. Tissue Adhesives Market by Formulation
  • 9. U.S. Tissue Adhesives Market Shares by Company (%): 2014
  • 10. Global Soft TIssue Repair Market Shares by Company (%): 2014
  • 11. Alliqua Hydress
  • 12. Alliqua SilverSeal
  • 13. sorbion sachet S
  • 14. sorbion sana
  • 15. Biovance®
  • 16. MiMedx vs. Aliiqua Product Revenues and Market Caps: 2014-2020
  • 17. Coloplast Wound Earnings Growth Rate (%) vs. Group: 2010-2014
  • 18. Coloplast Wound Revenues by Region: 2014
  • 19. Coloplast Wound Revenues by Hospital vs. Community Channels: 2014
  • 20. Coloplast Wound Revenues by Product vs. Total Market Channels: 2014
  • 21. Coloplast Negative Pressure extriCare
  • 22. Coloplast Silicon Foams
  • 23. Coloplast Hydrocolloids
  • 24. Wound Care Market Share Gain/Loss (%) by Company: 2013-2014
  • 25. Essex Revenue by Product Line (%): 2013
  • 26. Essex Revenue by Product Line (HKD Million): 2008-2013
  • 27. Essex Ophthalmic vs. Surface Wound Revenue (HKD Million): 2008-2013
  • 28. Direct Application of CureXcell into Wound Bed
  • 29. CureXcell Manufacturing Process from Whole Blood
  • 30. Composition of Wound Healing
  • 31. Role of Macrophages
  • 32. Diabetic Foot Ulcer/Venous Leg Ulcer
  • 33. Apligraf Usage
  • 34. Dermagraft Usage
  • 35. Percentage of Wounds Closed Vs. Control Across Advanced Wound Care Trials
  • 36. Average Baseline Wound Size Across Trials
  • 37. Comparison of Time to Close and Average Number of Treatments Across Advanced Wound Care Trials
  • 38. DFU Pivotal Trial (MC-102) Design
  • 39. dermaPACE® Technology
  • 40. Smith & Nephew Revenue by Segment (%): 2014
  • 41. Smith & Nephew Wound Care, Devices, Bioactives Revenue (USD Million): 2011-2018
  • 42. Wound Management Market Shares by Company (%): 2014
Back to Top